Gastroparesis Clinical Trial 2026: 6+ Companies, 8+ Emerging Therapies, and Key FDA Milestones Shaping the Future Treatment Landscape | DelveInsight

DelveInsight Business Research LLP has released its latest publication, "Gastroparesis Pipeline Insight, 2026," delivering in-depth analysis of 6+ companies and 6+ investigational drugs shaping the Gastroparesis treatment landscape. The report presents comprehensive profiles of pipeline candidates across clinical and preclinical stages. It also evaluates therapies by product category, development phase, route of administration, and molecular classification, while outlining discontinued and dormant programs within the space.

Stay informed with the most recent developments. Access DelveInsight's detailed Gastroparesis Pipeline Report to explore emerging therapies, leading innovators, and the future treatment outlook:
https://www.delveinsight.com/sample-request/gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Highlights from the Gastroparesis Pipeline Analysis
• On December 4, 2025, Vanda Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for tradipitant for the management of gastroparesis symptoms.
• In November 2025, Aclipse Therapeutics LLC ("Aclipse" or "the Company") today announced that it has entered into a clinical collaboration and Know-How Agreement with Mayo Clinic for the Phase 2 clinical development of M107, the Company's novel small molecule drug candidate being advanced as a potential disease modifying treatment for gastroparesis (i.e., stomach paralysis). The collaboration leverages the combined scientific and clinical expertise of both organizations to target macrophage related inflammation and seeks to address the biological cause of gastroparesis, a chronic and debilitating disease affecting stomach nerves and muscles resulting in stomach paralysis and delayed stomach emptying.
• In October 2025, CinDome Pharma Inc. initiated a clinical study to determine whether CIN-102 (deudomperidone) can reduce nausea severity in adults diagnosed with idiopathic gastroparesis.
• DelveInsight's findings indicate a competitive and dynamic landscape, with more than six active companies collectively developing over six investigational therapies targeting gastroparesis.
• Prominent companies advancing gastroparesis research include CinDome Pharma Inc., Aclipse Therapeutics, and others.
• Noteworthy pipeline candidates include Tradipitant, PCS12852, Naronapride, CNSA-001, Velusetrag, Camicinal, VLY-686 (Tradipitant), GM-611, among others.
Gain a deeper understanding of how the gastroparesis treatment landscape is transforming. Explore DelveInsight's comprehensive pipeline evaluation here:
https://www.delveinsight.com/sample-request/gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

The Gastroparesis Pipeline Report offers a detailed disease overview, an assessment of ongoing research programs, and a structured evaluation of key investigational therapies. It further identifies significant unmet medical needs in the gastroparesis treatment domain.

Gastroparesis: Disease Background
Gastroparesis is a chronic gastrointestinal disorder marked by delayed stomach emptying in the absence of any physical blockage. Common symptoms include persistent nausea, vomiting, abdominal bloating, early satiety, and stomach pain. The condition arises due to impaired gastric motility, often involving dysfunction in the nervous system and stomach musculature.
Although many cases are idiopathic, gastroparesis may also be associated with diabetes, prior surgeries, or infections. Increasing prevalence-particularly linked to rising diabetes and obesity rates-has led to greater awareness, though it is sometimes misdiagnosed as functional dyspepsia. Management remains complex, typically focusing on symptom control through medications, dietary modifications, and lifestyle interventions.

Gastroparesis Emerging Drug Spotlight
CIN-102: CinDome Pharma, Inc.
CIN-102 (deudomperidone) is an innovative compound created by applying deuteration technology to domperidone, a commonly prescribed therapy for nausea, vomiting, and gastroparesis. This orally administered therapy has been reformulated to optimize pharmacokinetics, aiming to provide sustained therapeutic benefit while significantly minimizing cardiac safety concerns.
Clinical studies have demonstrated favorable tolerability, with no sponsor-assessed drug-related adverse events or clinically meaningful laboratory abnormalities reported. CIN-102 is currently progressing through Phase II clinical development for gastroparesis treatment.

Insights Covered in the Gastroparesis Pipeline Report
• Comprehensive company profiles outlining ongoing therapeutic development programs for gastroparesis.
• Categorization of pipeline assets across early-, mid-, and late-stage clinical development.
• Evaluation of both active and inactive (discontinued or dormant) research initiatives.
• Detailed segmentation of investigational drugs by development stage, administration route, target receptor, mechanism of action, therapy type (monotherapy or combination), and molecular structure.
• Analysis of strategic collaborations, licensing agreements, partnerships, and funding activities driving market advancement.

Explore innovative therapies and ongoing clinical trials within the gastroparesis landscape by accessing the full report: https://www.delveinsight.com/sample-request/gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Companies in the Gastroparesis Space
Leading players advancing therapeutic research include CinDome Pharma Inc., Aclipse Therapeutics, and other emerging biopharmaceutical companies.

Gastroparesis Therapeutic Segmentation by Route of Administration (ROA)
Pipeline therapies are categorized under multiple administration routes, including:
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Gastroparesis Classification by Molecule Type
Gastroparesis investigational therapies are further grouped by molecular class, such as:
• Recombinant fusion proteins
• Small molecules
• Monoclonal antibodies
• Peptides
• Polymers
• Gene therapies

Download DelveInsight's latest Gastroparesis Pipeline Report to gain actionable insights into novel therapies and strategic industry developments: https://www.delveinsight.com/sample-request/gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Gastroparesis Pipeline Report Scope
• Global coverage
• Key companies: CinDome Pharma Inc., Aclipse Therapeutics, and others
• Pipeline therapies: Tradipitant, PCS12852, Naronapride, CNSA-001, Velusetrag, Camicinal, VLY-686 (Tradipitant), GM-611, among others
• Therapeutic segmentation by product type: Monotherapy, Combination therapy, Mono/Combination
• Clinical stage analysis: Discovery, Preclinical, Phase I, Phase II, and Phase III

Curious to know which companies are at the forefront of gastroparesis drug innovation? Discover the leaders and emerging challengers in DelveInsight's exclusive pipeline report: https://www.delveinsight.com/sample-request/gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Introduction
2. Executive Summary
3. Gastroparesis: Disease Overview
4. Pipeline Therapeutics
5. Therapeutic Evaluation
6. Analytical Perspective by DelveInsight
7. Late-Stage (Phase III) Products
8. Mid-Stage (Phase II) Products
9. CIN-102: CinDome Pharma, Inc.
10. Early-Stage (Phase I) Products
11. Discovery and Preclinical Programs
12. Inactive and Discontinued Products
13. Key Gastroparesis Companies
14. Major Pipeline Assets
15. Unmet Needs Analysis
16. Market Drivers and Challenges
17. Future Outlook and Conclusions
18. Analyst Insights
19. Key Companies Overview
20. Appendix

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a globally recognized healthcare market research and consulting organization delivering actionable business intelligence to support strategic decision-making. Backed by experienced analysts and deep expertise in life sciences and healthcare, the firm provides tailored research solutions and real-time insights to clients worldwide, helping them remain competitive in a rapidly evolving market landscape.

This release was published on openPR.